Progenitor exhausted CD8+ T (Tpex) cells have emerged as a pivotal component in tumor immunotherapy due to their unique ability to self-renew and rapidly proliferate. These cells have shown promise in expanding and differentiating into functional exhausted CD8+ T cells, significantly enhancing clinical outcomes.
Tpex cells: A game-changer in targeted tumor immunotherapy retrieved 8 August 2024 from https://medicalxpress.com/news/2024-08-tpex-cells-game-changer-tumor.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
CD133 hematopoietic stem and progenitor cell markerProminin-1, also known as CD133, Antigen AC133, PROM1, PROML1, and MSTP061, is a hematopoietic stem and progenitor cell (HSPC) marker.
Read more »
The interplay of liver cancer stem cells and immune cells in tumor microenvironmentThe complex dynamics between liver cancer stem cells (CSCs) and immune cells within the tumor microenvironment (TME) are central to the progression of liver cancer. These interactions are critical in creating an immunosuppressive setting that significantly impacts the response to immunotherapy.
Read more »
Distinct T-cell signatures observed at different stages of type 1 diabetes developmentA study conducted at the University of Eastern Finland found distinct signatures in CD8+ T cells in blood samples from children with newly diagnosed type 1 diabetes and in autoantibody-positive children who later developed type 1 diabetes. The study was published in the journal Diabetes.
Read more »
Targeted drug treatment leads tumor cells to imitate viral infection, researchers discoverA number of cancers, including certain brain and liver tumors, as well as myeloid leukemias, are driven by mutations in the enzyme isocitrate dehydrogenase 1, or IDH1. Drugs that block mutated IDH1 (mIDH1) have recently come onto the market and effectively slow tumor growth, but the exact mechanism at work to stall tumors is still unclear.
Read more »
Knockout of CD5 on CAR T cells shown to boost anti-tumor efficacyThe effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on the surface of T cells, according to a preclinical study from investigators at the University of Pennsylvania's Perelman School of Medicine and...
Read more »
Tumor suppressor protein Par-4 found to trigger unique cell death pathway in cancer cellsA team of researchers at NYU Abu Dhabi, led by Professor Sehamuddin Galadari, has discovered that the tumor suppressor protein Prostate apoptosis response-4 (Par-4) can cause a unique type of cell death called ferroptosis in human glioblastoma—the most common and aggressive type of brain tumor—while sparing healthy cells.
Read more »